Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biologic dose reduction and discontinuation in inflammatory arthritis
2017-001970-41Phase 4Completed
- Sponsor
- MD, PhD Salome Kristensen
- Start
- Sep 2017
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of abatacept, adalimumab, certolizumab pegol, etanercept, golimumab and 2 more in rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) (2 arms), sponsored by MD, PhD Salome Kristensen. Primary endpoint: Co-primary endpoint. Started Sep 2017; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)psoriatic arthritis (PsA)axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on 2017-001970-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001970-41.